Regeneron's (REGN) Transparency Questioned as Investors Sue Over Eylea Pricing Practices– Hagens Berman

SAN FRANCISCO, March 06, 2025 (GLOBE NEWSWIRE) -- Biotechnology giant Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is embroiled in a securities class action lawsuit, alleging the company misled investors about its pricing practices for its blockbuster drug Eylea. The lawsuit, filed in the Southern District of New York, seeks to represent investors who purchased Regeneron securities between November 2, 2023, and October 30, 2024.   Hagens Berman urges investors who purchased Regeneron shares and suffered s ...